RxDoctor Payments Data

Patrick Hurley, MD

Urology · Southfield, MINPI 1508819681

Payments from drug & device makers

$9,198in general payments, 2019–2025

Across 383 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Astellas Pharma US Inc$874
  • Boston Scientific$781
  • AbbVie$553
  • Johnson & Johnson$543
  • Coloplast$493
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$8,91597%
  • Education$2833%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,198 in reported general payments places this provider in the 75th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$494,685
Medicare patients
1,143
Services billed
7,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide39$566,973
MyrbetriqMirabegron122$103,286
Tamsulosin Hcl1,775$34,009
Mirabegron ErMirabegron41$25,033
Finasteride960$18,239
GemtesaVibegron18$16,498
Alfuzosin Hcl ErAlfuzosin Hcl419$11,524
Dutasteride254$11,185
Tolterodine Tartrate ErTolterodine Tartrate109$9,435
Potassium Citrate ErPotassium Citrate79$7,462
Testosterone39$6,666
Bicalutamide56$6,385
Solifenacin Succinate165$5,805
Trimethoprim38$2,237
Oxybutynin Chloride ErOxybutynin Chloride68$2,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$874$670,259161 claims
Sumitomo Pharma America, Inc.Gemtesa$134$16,49818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 400 urology providers in Michigan.

Other urology in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →